公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 2 | 1 | |
2017 | The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21) | SUNG-HSIN KUO ; Tsai H.-J.; CHUNG-WU LIN ; KUN-HUEI YEH ; Lee H.-W.; Wei M.-F.; CHIA-TUNG SHUN ; MING-SHIANG WU ; PING-NING HSU ; Chen L.-T.; ANN-LII CHENG | Journal of Pathology | 12 | 12 | |
2002 | Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells | Chuang S.-E.; Yeh P.-Y.; YEN-SHEN LU ; Lai G.-M.; Liao C.-M.; Gao M.; ANN-LII CHENG | Biochemical Pharmacology | 161 | 138 | |
1998 | Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity | Kuo M.-L.; Shen S.-C.; CHIH-HSIN YANG ; Chuang S.-E.; ANN-LII CHENG ; Huang T.-S. | Oncogene | 39 | 35 | |
2012 | BCL10GFP fusion protein as a substrate for analysis of determinants required for mucosa-associated lymphoid tissue 1 (MALT1)-mediated cleavage | Jou, Shin-Yi; Chang, Chien-Chih; Wu, Chun-Hsien; MEI-RU CHEN ; CHING-HWA TSAI ; Chuang, Wen-Hui; Chen, Yun-Hui; ANN-LII CHENG ; SHIN-LIAN DOONG | Journal of biomedical science | 1 | | |
2016 | Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis | I-CHUN CHEN ; CHING-HUNG LIN ; I-SHIOW JAN ; ANN-LII CHENG ; YEN-SHEN LU | Journal of the Formosan Medical Association | 18 | 11 | |
2015 | Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy | YEN-SHEN LU ; WEI-WU CHEN ; CHING-HUNG LIN ; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; BANG-BIN CHEN ; Chao T.-C.; Huang S.-M.; CHIUN-SHENG HUANG ; TIFFANY TING-FANG SHIH ; ANN-LII CHENG ; Taiwan Breast Cancer Consortium | Clinical Cancer Research | 65 | 59 | |
2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
2014 | Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: Despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverse | SUNG-HSIN KUO ; Tsai H.-J.; Weng W.-H.; Li C.-C.; KUN-HUEI YEH ; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 3 | 3 | |
1998 | Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma | ANN-LII CHENG ; KUN-HUEI YEH ; Fine R.L.; Chuang S.-E.; Yang C.-H.; Wang L.-H.; DING-SHINN CHEN | Hepato-Gastroenterology | 41 | 33 | |
1989 | Bone marrow involvement in non-Hodgkin's lymphoma. | HONG-SHIEE LAI ; HWEI-FANG TIEN ; Hsieh H.C.; YAO-CHANG CHEN ; Su I.J.; Wang C.H.; Liu M.C.; ANN-LII CHENG ; MING-CHING SHEN ; Liu C.H. | Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association | 11 | 0 | |
2012 | Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A | CHAO YUAN HUANG ; CHIA-CHENG WEI ; Chen K.-C.; Chen H.-J.; ANN-LII CHENG ; Chen K.-F. | Cancer Letters | 29 | 28 | |
2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
2011 | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A | Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; PEI-JER CHEN ; ANN-LII CHENG | Molecular Cancer Therapeutics | 36 | 32 | |
2016 | BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer | KUO-HSING CHEN ; Lin Y.-L.; JAU-YU LIAU ; JIA-HUEI TSAI ; LI-HUI TSENG ; LIANG-IN LIN ; JIN-TUNG LIANG ; BEEN-REN LIN ; JI-SHIANG HUNG ; YIH-LEONG CHANG ; KUN-HUEI YEH ; ANN-LII CHENG | Medical Oncology | 19 | 18 | |
2008 | Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells | Lin H.-J.L.; Zuo T.; CHING-HUNG LIN ; Chieh T.K.; Liyanarachchi S.; Sun S.; Shen R.; Deatherage D.E.; Potter D.; Asamoto L.; Lin S.; Yan P.S.; ANN-LII CHENG ; Ostrowski M.C.; Huang T.H.-M. | Cancer Research | 58 | 55 | |
2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 618 | 595 | |
2022 | Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review | Graham, Jeffrey; Vogel, Arndt; ANN-LII CHENG ; Bjarnason, Georg A; Neal, Joel W | Cancer treatment reviews | 2 | 2 | |
2020 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG ; Rimassa L. | Future Oncology | 50 | 49 | |
2018 | Cabozantinib in patients with advanced and progressing hepatocellular carcinoma | Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG ; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. | New England Journal of Medicine | 1553 | 1405 | |